Short answer
LB PHARMACEUTICALS INC (LBRX) filed its Q1 2026 10-Q quarterly report on May 12, 2026 for the quarter ended Mar 31, 2026.
Q1 2026 key financials · XBRL
- Net income
- −$19M
- EPS (diluted)
- −$0.67
Source: XBRL data from the LB PHARMACEUTICALS INC (LBRX) Q1 2026 10-Q on SEC EDGAR. USD.
LB PHARMACEUTICALS INC Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- No explicit new or changed risk factors identified versus the most recent 10-K
- Financial runway: $365.6 million in cash, cash equivalents, and marketable securities funding operations for at least 12 months
- Development risk: LB-102 schizophrenia trials rely on subjective PANSS assessments, increasing outcome variability
- Regulatory risk: FDA may require additional preclinical studies or protocol amendments before future clinical trials
- Royalty obligation: payments up to 2.75% of worldwide LB-102 net sales through December 31, 2035
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other LB PHARMACEUTICALS INC quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.